Abstract:Background As an age-related syndrome, frailty may play a central role in poor health among older adults. Sarcopenia overlaps with the physical domain of frailty, and most existing studies have analyzed the associated factors of frailty and sarcopenia as an isolated state. Perturbations in metabolism may play an important role in the presence of frailty or sarcopenia; however, the metabolites associated with frailty, especially overlapping with sarcopenia remain unclear. In this study, we aimed to explore whether amino acids, carnitines, acylcarnitines and lysophosphatidylcholines, as specific panels, are significantly correlated with frailty, especially overlapping with sarcopenia, to gain insight into potential biomarkers and possible biological mechanisms and to facilitate their management. Methods We applied a targeted high-performance liquid chromatography-tandem mass spectrometry approach in serum samples from 246 Chinese older men (age 79.2 ± 7.8 years) with frailty ( n = 150), non-frailty ( n = 96), frailty and sarcopenia ( n = 52), non-frail and non-sarcopenic control ( n = 85). Frailty was evaluated using Freid phenotype criteria, sarcopenia was defined by diagnostic algorithm of Asian Working Group on Sarcopenia, and the participants were diagnosed as frailty and sarcopenia when they met the evaluation criteria of both frailty and sarcopenia. A panel of 29 metabolomic profiles was assayed and included different classes of amino acids, carnitines, acylcarnitines, and lysophosphatidylcholines (LPCs). Multivariate logistic regression was used to screen the metabolic factors contributing to frailty status, and orthogonal partial least squares discriminant analysis was used to explore important factors and distinguish different groups. Results In older men demonstrating the frail phenotype, amino acid perturbations included lower tryptophan and higher glycine levels. With regard to lipid metabolism, the frailty phenotype was characterized by lower concentrations of isovalerylcarnitine (C5), LPC16:0 and LPC18:2, while higher levels of octanoyl-L-carnitine (C8), decanoyl-L-carnitine (C10), dodecanoyl-L-carnitine (C12) and tetradecanoyl-L-carnitine (C14). After adjusting for several clinical confounders, tryptophan, LPC18:2, LPC 16:0 and C5 were negatively correlated with frailty, and C8 and C12 were positively related to frailty. We preliminarily identified metabolic profiles (LPC16:0, LPC18:2, glycine and tryptophan) that may distinguish older men with frailty from those without frailty. Importantly, a set of serum amino acids and LPCs (LPC16:0, LPC18:2, and tryptophan) was characterized in the metabotype of older adults with an overlap of frailty and sarcopenia. The metabolites that were most discriminating of frailty status implied that the underlying mechanism might be involved in antioxidation and mitochondrial dysfunction. Conclusions These present metabolic analyses may provide valuable information on the potential biomarkers and possible biological mechanisms of frailty, and overlapping sarcopenia. The findings obtained may offer insight into their management in older adults.

Proteo‐metabolomic insights for early dual physical and cognitive impairments: A search for biomarkers of healthy aging based on muscle–brain crosstalk

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life

Plasma metabolomic markers underlying skeletal muscle mitochondrial function relationships with cognition and motor function

Circulating Metabolome in Relation to Cognitive Impairment: a Community-Based Cohort of Older Adults

Metabolic kinetics and muscle and brain health markers in older adults, and the role of age and presence of chronic morbidities: a large cross-sectional cohort study

Comprehensive serum metabolic and proteomic characterization on cognitive dysfunction in Parkinson’s disease

Integrated Multi-Omics Analysis Identifies Disrupted Branched-Chain Amino Acid Catabolism As Causal for Sarcopenia

Integrated analysis of plasma proteome and cortex single-cell transcriptome reveals the novel biomarkers during cortical aging

Specific Metabolites Involved in Antioxidation and Mitochondrial Function Are Correlated With Frailty in Elderly Men

Metabolic signatures and risk of sarcopenia in suburb-dwelling older individuals by LC-MS–based untargeted metabonomics

Metabolomic signatures for the longitudinal reduction of muscle strength over 10 years

Proteostatic modulation in brain aging without associated Alzheimer's disease-and age-related neuropathological changes

Possible-sarcopenic screening with disturbed plasma amino acid profile in the elderly

Novel metabolic and lipidomic biomarkers of sarcopenia

Serum metabolome profiling in patients with mild cognitive impairment reveals sex differences in lipid metabolism

Sex and aging signatures of proteomics in human cerebrospinal fluid identify distinct clusters linked to neurodegeneration.

Specific lysophosphatidylcholine and acylcarnitine related to sarcopenia and its components in older men

Plasma metabolomics and lipidomics signatures of motoric cognitive risk syndrome in community-dwelling older adults

The mediation roles of intermuscular fat and inflammation in muscle mitochondrial associations with cognition and mobility

Combined Plasma DHA-Containing Phosphatidylcholine PCaa C38:6 and Tetradecanoyl-Carnitine as an Early Biomarker for Assessing the Mortality Risk among Sarcopenic Patients